In This Issue
Staging of the Mediastinum
Consolidation Chemotherapy after Chemoradiation?
High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation
Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials
Lung Cancer and Prognosis in Taiwan
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System
Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer
WT1 Promotes Invasion of NSCLC via Suppression of CDH1
A Prediction Model for Pathologic N2 Disease in Lung Cancer Patients with a Negative Mediastinum by Positron Emission Tomography
Is Consolidation Chemotherapy after Concurrent Chemo-Radiotherapy Beneficial for Patients with Locally Advanced Non–Small-Cell Lung Cancer?
KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value
Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?
Overexpression of EPH Receptor B2 in Malignant Mesothelioma Correlates with Oncogenic Behavior
Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma
Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?
Sarcomatoid Mesothelioma with Osteoid Differentiation
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib